Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


1 Am J Hematol
7 Ann Hematol
1 Biochem Pharmacol
2 Blood
1 BMC Cancer
1 Bone Marrow Transplant
1 Eur J Immunol
2 Exp Hematol
1 Gene
1 Int J Hematol
6 Leuk Lymphoma
4 Leuk Res
1 N Engl J Med

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. SHORT NJ, Jabbour E, Albitar M, de Lima M, et al
    Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts.
    Am J Hematol. 2018 Nov 5. doi: 10.1002/ajh.25338.
    PubMed     Text format     Abstract available

    Ann Hematol

  2. ZAUNER F, Tayeb S, Panagiota V, Rababah M, et al
    Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?
    Ann Hematol. 2018;97:1111-1113.
    PubMed     Text format    

  3. CHAN TSY, Kwong YL
    Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Ann Hematol. 2018;97:371-373.
    PubMed     Text format    

  4. FUREDER W, Sperr WR, Gleixner K, Thalhammer R, et al
    Major response of PNH to an AML chemotherapy protocol.
    Ann Hematol. 2018;97:1487-1488.
    PubMed     Text format    

  5. CASTELLI A, Mosca-Siez ML, Riccomagno P, Patriarca A, et al
    Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.
    Ann Hematol. 2018;97:1485-1486.
    PubMed     Text format    

  6. PINTO AL, Ferreira G, Carda JP, Gomes M, et al
    Isolated Richter's syndrome of the brain: diagnosis in the eye of the beholder.
    Ann Hematol. 2018;97:1509-1511.
    PubMed     Text format    

  7. SHALLIS RM, Xu ML, Curtis SA, Medoff E, et al
    Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Ann Hematol. 2018;97:2245-2248.
    PubMed     Text format    

  8. BUCCHERI V, Barreto WG, Fogliatto LM, Capra M, et al
    Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Ann Hematol. 2018;97:2269-2278.
    PubMed     Text format     Abstract available

    Biochem Pharmacol

  9. WANG LJ, Lee YC, Huang CH, Shi YJ, et al
    Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-alpha upregulation.
    Biochem Pharmacol. 2018 Nov 7. pii: S0006-2952(18)30472.
    PubMed     Text format     Abstract available


  10. ABDUL-AZIZ AM, Sun Y, Hellmich C, Marlein CR, et al
    Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment.
    Blood. 2018 Nov 6. pii: blood-2018-04-845420. doi: 10.1182/blood-2018-04-845420.
    PubMed     Text format     Abstract available

  11. LEBECQUE B, Lechevalier N
    B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia.
    Blood. 2018;132:2107.
    PubMed     Text format    

    BMC Cancer

  12. DI FELICE E, Roncaglia F, Venturelli F, Mangone L, et al
    The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
    BMC Cancer. 2018;18:1069.
    PubMed     Text format     Abstract available

    Bone Marrow Transplant

  13. KIM HJ, Sohn HJ, Hong JA, Lee HJ, et al
    Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.
    Bone Marrow Transplant. 2018 Nov 8. pii: 10.1038/s41409-018-0383.
    PubMed     Text format    

    Eur J Immunol

  14. EWEN EM, Pahl JHW, Miller M, Watzl C, et al
    KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
    Eur J Immunol. 2018;48:355-365.
    PubMed     Text format     Abstract available

    Exp Hematol

  15. TIJCHON E, van Emst L, Yuniati L, van Ingen Schenau D, et al
    Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
    Exp Hematol. 2018;60:57-62.
    PubMed     Text format     Abstract available

  16. SHANG J, Chen WM, Wang ZH, Wei TN, et al
    CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis.
    Exp Hematol. 2018 Nov 2. pii: S0301-472X(18)30873.
    PubMed     Text format     Abstract available


  17. CHANDRAN RK, Geetha N, Sakthivel KM, Aswathy CG, et al
    Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
    Gene. 2018 Nov 3. pii: S0378-1119(18)31143-0. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available

    Int J Hematol

  18. RAKSZAWSKI K, Miki K, Claxton D, Wagner H, et al
    Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
    Int J Hematol. 2018;108:348-350.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  19. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Text format     Abstract available

  20. TAO S, Wang C, Chen Y, Deng Y, et al
    Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1504941.
    PubMed     Text format     Abstract available

  21. RODRIGUEZ CM, Bussi C, Arroyo DS, Sastre D, et al
    Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Nov 8:1-5. doi: 10.1080/10428194.2018.1529309.
    PubMed     Text format    

  22. NABHAN C, Kamat S, Karl Kish J
    Acute myeloid leukemia in the elderly: what constitutes treatment value?
    Leuk Lymphoma. 2018 Nov 8:1-7. doi: 10.1080/10428194.2018.1520992.
    PubMed     Text format     Abstract available

  23. GURU MURTHY GS, Pondaiah SK, Abedin S, Atallah E, et al
    Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
    Leuk Lymphoma. 2018 Nov 8:1-8. doi: 10.1080/10428194.2018.1522442.
    PubMed     Text format     Abstract available

  24. SOUMERAI JD, Ni A, Xing G, Huang J, et al
    Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782.
    PubMed     Text format     Abstract available

    Leuk Res

  25. RAJ RV, Abedin SM, Atallah E
    Incorporating newer agents in the treatment of acute myeloid leukemia.
    Leuk Res. 2018;74:113-120.
    PubMed     Text format     Abstract available

  26. THEUNISSEN PMJ, de Bie M, van Zessen D, de Haas V, et al
    Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Leuk Res. 2018 Oct 22. pii: S0145-2126(18)30443.
    PubMed     Text format     Abstract available

  27. MIYATA S, Wang LY, Kitanaka S
    3EZ, 20Ac-ingenol induces cell-specific apoptosis in cyclin D1 over-expression through the activation of ATR and downregulation of p-Akt.
    Leuk Res. 2018;64:46-51.
    PubMed     Text format     Abstract available

  28. GARCIA TB, Fosmire SP, Porter CC
    Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Leuk Res. 2018;64:30-33.
    PubMed     Text format     Abstract available

    N Engl J Med

  29. EBERT BL, Kronke J
    Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.
    N Engl J Med. 2018;379:1873-1874.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.